PMID- 31112346
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230201
IS  - 1098-2264 (Electronic)
IS  - 1045-2257 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Jan
TI  - Cytogenetic analysis of 130 renal oncocytomas identify three distinct and 
      mutually exclusive diagnostic classes of chromosome aberrations.
PG  - 6-12
LID - 10.1002/gcc.22766 [doi]
AB  - The cytogenetic alterations in renal oncocytoma (RO) are poorly understood. We 
      analyzed 130 consecutive RO for karyotypic alterations. Clonal chromosome 
      abnormalities were identified in 63 (49%) cases, which could be categorized into 
      three classes of mutually exclusive cytogenetic categories. Class 1 (N = 20) RO 
      had diploid karyotypes with characteristic 11q13 rearrangement in balanced 
      translocations with 10 or more different chromosome partners in all cases. We 
      identified recurrent translocation partners at 5q35, 6p21, 9p24, 11p13-14, and 
      11q23, and confirmed that CCND1 gene rearrangement at 11q13 utilizing 
      fluorescence in situ hybridization (FISH). Class 2 RO (N = 25) exhibited 
      hypodiploid karyotypes with loss of chromosome 1 and/or losses of Y in males and 
      X in females in all cases. The class 3 tumors comprising of 18 cases showed 
      diverse types of abnormalities with the involvement of two or more chromosomes 
      exclusive of abnormalities seen in classes 1 and 2 tumors. Furthermore, 
      karyotypically uninformative cases were subjected to FISH analysis to identify 
      classes 1 and 2 abnormalities. In this group, we found similar frequencies of 
      CCND1 rearrangement, loss of chromosome 1 or Y as with karyotypically abnormal 
      cases. We validated our results against 91 tumors from the Mitelman database. 
      Correlation of clinical data with all the three classes of ROs showed no clear 
      evidence of overall patient survival. Our findings support the hypothesis that RO 
      exhibit three principal cytogenetic categories, which may have different roles in 
      initiation and/or progression. These cytogenetic markers provide a key tool in 
      the diagnostic evaluation of RO.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Anderson, Christopher B
AU  - Anderson CB
AD  - Department of Urology, Columbia University Irving Medical Center, New York, New 
      York.
FAU - Lipsky, Michael
AU  - Lipsky M
AD  - Department of Urology, Columbia University Irving Medical Center, New York, New 
      York.
FAU - Nandula, Subhadra V
AU  - Nandula SV
AD  - Cancer Genetics, Inc., Rutherford, New Jersey.
FAU - Freeman, Christopher E
AU  - Freeman CE
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
FAU - Matthews, Thomas
AU  - Matthews T
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
FAU - Walsh, Caitlin E
AU  - Walsh CE
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
FAU - Li, Gen
AU  - Li G
AD  - Department of Biostatistics, Columbia University Irving Medical Center, New York, 
      New York.
FAU - Szabolcs, Matthias
AU  - Szabolcs M
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
FAU - Mansukhani, Mahesh M
AU  - Mansukhani MM
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
FAU - McKiernan, James M
AU  - McKiernan JM
AD  - Department of Urology, Columbia University Irving Medical Center, New York, New 
      York.
FAU - Murty, Vundavalli V
AU  - Murty VV
AUID- ORCID: 0000-0003-1603-6414
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center, New York, New York.
LA  - eng
PT  - Journal Article
DEP - 20190604
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
SB  - IM
OTO - NOTNLM
OT  - 11q13 rearrangement
OT  - cyclin D1
OT  - cytogenetics
OT  - loss of chromosome 1
OT  - renal oncocytoma
EDAT- 2019/05/22 06:00
MHDA- 2019/05/22 06:01
CRDT- 2019/05/22 06:00
PHST- 2019/05/15 00:00 [revised]
PHST- 2019/03/02 00:00 [received]
PHST- 2019/05/15 00:00 [accepted]
PHST- 2019/05/22 06:00 [pubmed]
PHST- 2019/05/22 06:01 [medline]
PHST- 2019/05/22 06:00 [entrez]
AID - 10.1002/gcc.22766 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2020 Jan;59(1):6-12. doi: 10.1002/gcc.22766. Epub 2019 
      Jun 4.